Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study

Niels Heersche; Daan A C Lanser; Esther Oomen-de Hoop; Attila Içli; Peter de Bruijn; Marthe S Paats; Elisabeth F C van Rossum; Stijn L W Koolen; Ron H N van Schaik; Anne-Marie C Dingemans; G D Marijn Veerman; Ron H J Mathijssen

doi:10.1002/cac2.70030

Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study

Niels Heersche, Daan A C Lanser, Esther Oomen-de Hoop, Attila Içli, Peter de Bruijn, Marthe S Paats, Elisabeth F C van Rossum, Stijn L W Koolen, Ron H N van Schaik, Anne-Marie C Dingemans, G D Marijn Veerman, Ron H J Mathijssen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

26 Downloads (Pure)

Original language	English
Journal	Cancer Communications
DOIs	https://doi.org/10.1002/cac2.70030
Publication status	E-pub ahead of print - 1 May 2025

Access to Document

10.1002/cac2.70030Licence: CC BY-NC-ND

Semaglutide impairs bioavailability of alectinibFinal published version, 425 KBLicence: CC BY-NC-ND

Cite this

Heersche, N., Lanser, D. A. C., Oomen-de Hoop, E., Içli, A., de Bruijn, P., Paats, M. S., van Rossum, E. F. C., Koolen, S. L. W., van Schaik, R. H. N., Dingemans, A.-M. C., Veerman, G. D. M., & Mathijssen, R. H. J. (2025). Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study. Cancer Communications. Advance online publication. https://doi.org/10.1002/cac2.70030

@article{e5cdc6ae4df64e02a13253900119a1a7,

title = "Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study",

author = "Niels Heersche and Lanser, \{Daan A C\} and \{Oomen-de Hoop\}, Esther and Attila I{\c c}li and \{de Bruijn\}, Peter and Paats, \{Marthe S\} and \{van Rossum\}, \{Elisabeth F C\} and Koolen, \{Stijn L W\} and \{van Schaik\}, \{Ron H N\} and Dingemans, \{Anne-Marie C\} and Veerman, \{G D Marijn\} and Mathijssen, \{Ron H J\}",

year = "2025",

month = may,

day = "1",

doi = "10.1002/cac2.70030",

language = "English",

journal = "Cancer Communications",

issn = "1000-467X",

publisher = "John Wiley \& Sons Inc.",

}

Heersche, N, Lanser, DAC, Oomen-de Hoop, E, Içli, A, de Bruijn, P , Paats, MS , van Rossum, EFC , Koolen, SLW , van Schaik, RHN , Dingemans, A-MC , Veerman, GDM & Mathijssen, RHJ 2025, 'Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study', Cancer Communications. https://doi.org/10.1002/cac2.70030

TY - JOUR

T1 - Semaglutide impairs bioavailability of alectinib

T2 - a note of warning based on a cross-over pharmacokinetic drug-drug interaction study

AU - Heersche, Niels

AU - Lanser, Daan A C

AU - Oomen-de Hoop, Esther

AU - Içli, Attila

AU - de Bruijn, Peter

AU - Paats, Marthe S

AU - van Rossum, Elisabeth F C

AU - Koolen, Stijn L W

AU - van Schaik, Ron H N

AU - Dingemans, Anne-Marie C

AU - Veerman, G D Marijn

AU - Mathijssen, Ron H J

PY - 2025/5/1

Y1 - 2025/5/1

U2 - 10.1002/cac2.70030

DO - 10.1002/cac2.70030

M3 - Article

C2 - 40308149

SN - 1000-467X

JO - Cancer Communications

JF - Cancer Communications

ER -